ArticleJCEM case reports2026
Unanticipated remission of primary hyperparathyroidism following cinacalcet.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hyperparathyroidism (PHPT) is the most common etiology of hypercalcemia in an ambulatory setting and often arises from adenomatous growth of one (occasionally more than one) parathyroid gland. Patients with severe and symptomatic hypercalcemia, renal insufficiency, nephrolithiasis, osteoporosis, and younger than 50 are candidates for surgical removal of parathyroid adenoma(s). Medical treatment with a calcimimetic agent is offered to improve severe hypercalcemia when surgery is refused or considered unsafe. Here, we report a 68-year-old man with severe hypercalcemia due to PHPT and coronary artery disease who had to undergo percutaneous coronary intervention and stent placement. Surgery for PHPT was delayed for 6 months, and he received cinacalcet to lower serum calcium. He developed hypocalcemia 6 months later. After discontinuation of cinacalcet, his serum calcium remained normal. Ultrasonography of the anterior neck showed again a hypoechoic lesion posterior to the right thyroid lobe (presumed to be a parathyroid adenoma) but with smaller dimensions. This case highlights a rare but clinically significant phenomenon: the possibility of durable remission and anatomical regression of parathyroid adenoma following cinacalcet administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.